Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thailand to Buy Generic Plavix in India, Snubs Sanofi (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Thailand is ordering 2 million doses of generic Plavix from India after failing to win large enough discounts for the blood-thinner made by Bristol-Myers Squibb Co. and Sanofi-Aventis SA. As many as four Indian drugmakers are vying for the contract, according to Vichai Chokevivat, chairman of the Government Pharmaceutical Organization. The supplies will help meet Thailand's demand for between 4 million and 5 million Plavix tablets a year and cut the cost of treating the country's poorest heart-disease patients. The state-run drugmaker, which had initially sought 500,000 doses of generic Plavix, or clopidogrel, expects to pay between 5 baht and 5.50 baht for the pills. Sanofi offered to sell Plavix at 27 baht per tablet, with an added incentive of supplying 3.4 million tablets for the same cost as 1 million. "We proposed a program that would allow the Ministry of Public Health to supply, at no additional cost, our high-quality heart treatment," Sanofi spokesman Jean-Marc Podvin said. "However, the ministry has focused only on price and has insisted repeatedly on sourcing generics of Plavix of unknown quality." Thailand is using a World Trade Organization provision that allows governments to permit generic-drug production without the patent owners' consent in some cases. Thailand is already buying copies of the AIDS drug efavirenz, marketed as Stocrin by Merck & Co. and as Sustiva by Bristol-Myers, from an Indian unit of Mylan Laboratories Inc. Thailand says copying the drugs will allow the government to provide free medicine to a larger share of the country's poorest citizens, including its 220,000 HIV sufferers. The Pharmaceutical Research and Manufacturers of America says issuing so-called compulsory licenses removes the incentive for companies to invest in research, and that its members would retaliate by not introducing new drugs in Thailand. (Click here for more - May Require Free Registration

You may also be interested in...



US FDA Oncology AdComm's Pediatric Study Reviews Go Virtual

ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.

Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework

Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel